ArticleVeterinary medicine and science2025
Portulaca oleracea Extract Ameliorates Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Male Sprague-Dawley Rats.
Article in Veterinary medicine and science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benign prostatic hyperplasia (BPH) is a distressing health problem that can cause serious complications in aging men. Androgens are implicated in the causation of BPH. Portulaca oleracea (PO) is a natural product with diverse pharmacological effects. The objective of this study was to investigate the effect of PO in a rat model of testosterone propionate (TP)-induced BPH and explore the underlying mechanisms. Thirty-five Sprague-Dawley (SD) rats were divided into the following equal groups (n = 7): normal control (NC) group, TP (3 mg/kg) group, finasteride (10 mg/kg) group, 25 and 50 mg/kg PO groups. At the end of the experiment, the body weights (BWs) of the rats were measured before they were euthanized to the establishment obtain serum and prostate weight (PW). TP-induced levels of androgen-related proteins in the prostate were also investigated. In the TP group, prostate size, BW, serum DHT level, prostate epithelial cell thickness and androgen-related protein level were higher than those in the NC group (p < 0.001). PO reversed TP-induced BPH in a dose-dependent manner (p < 0.01) and its effect was similar to that of finasteride. A similar effect of PO on the androgen-related protein level was also observed. We successfully established a TP-induced BPH rat model. This is the first study to demonstrate that inhibition of androgen-related proteins using PO can alleviate BPH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.